Supernus Pharmaceuticals and Indivior agreed to merge in an all-stock transaction, combining commercial CNS portfolios and pipeline overlap across addiction, depression and Parkinson’s disease. Under the reported terms, Indivior shareholders will receive 0.2683 Supernus shares per Indivior share, with the combined company planned to be called Supernus. The merger is subject to regulatory approvals and expected to close in the second half of 2026. Companies projected about $125 million in annual cost synergies by the end of 2027, aimed at streamlining corporate functions and increasing R&D flexibility. Indivior brings buprenorphine-based extended-release assets focused on addiction, while Supernus contributes the FDA-approved apomorphine infusion device SPN-830 (ONAPGO) for Parkinson’s motor fluctuations.